REVEAL GENOMICS PRESENTS THE LATEST HER2DX® DATA IN HER2+ BREAST CANCER AT SABCS 2022
San Antonio (ots/PRNewswire) - - The HER2DX® risk score predicted long-term survival outcomes in clinically low-risk patients in APT and ATEMPT clinical trials. - The HER2DX® pCR score predicted response to chemotherapy in combination with trastuzumab and pertuzumab in DAPHNe and GOM clinical trials. - HER2DX®️ is the first genomic test in the world specialized in ...
plus